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The human fibroblast growth factor (FGF) family comprises 22 structurally related poly-
peptides that play crucial roles in neuronal functions, development, and metabolism. 
FGFs are classified as intracrine, paracrine, and endocrine FGFs based on their action 
mechanisms. Paracrine and endocrine FGFs are secreted signaling molecules by acting 
via cell-surface FGF receptors (FGFRs). Paracrine FGFs require heparan sulfate as a 
cofactor for FGFRs. In contrast, endocrine FGFs, comprising FGF19, FGF21, and FGF23, 
require α-Klotho or β-Klotho as a cofactor for FGFRs. Endocrine FGFs, which are specific 
to vertebrates, lost heparan sulfate-binding affinity and acquired a systemic signaling 
system with α-Klotho or β-Klotho during early vertebrate evolution. The phenotypes of 
endocrine FGF knockout mice indicate that they play roles in metabolism including bile 
acid, energy, and phosphate/active vitamin D metabolism. Accumulated evidence for the 
involvement of endocrine FGFs in human genetic and metabolic diseases also indicates 
their pathophysiological roles in metabolic diseases, potential risk factors for metabolic 
diseases, and useful biomarkers for metabolic diseases. The therapeutic utility of endo-
crine FGFs is currently being developed. These findings provide new insights into the 
physiological and pathophysiological roles of endocrine FGFs and potential diagnostic 
and therapeutic strategies for metabolic diseases.
Keywords: biomarker, disease, endocrine, FGF, Klotho, metabolism, mutation, polymorphism
introduction
Cell–cell communication with secreted signaling molecules ensures proper development and 
metabolism. Most fibroblast growth factors (FGFs) are well-established secreted signaling proteins 
that play critical roles in development and metabolism. The FGF family comprises 22 structurally 
and evolutionarily related proteins including FGF1–FGF23 in humans and mice (1). The human 
and mouse FGF families do not include FGF15 and FGF19, respectively, as they are orthologs. FGFs 
are classified as intracrine, paracrine, and endocrine FGFs by their action mechanisms (Figure 1A). 
Paracrine and endocrine FGFs, which comprise 15 and 3 FGFs, respectively, are secreted signaling 
proteins. In contrast, intracrine FGFs, which comprise four FGFs, are intracellular proteins that are 
not functionally related to paracrine or endocrine FGFs (1).
Endocrine FGFs comprise FGF19, FGF21, and FGF23. The mouse is a mammalian model that 
is useful for investigating gene functions through gene targeting. All endocrine FGF knockout mice 
have been generated and extensively analyzed, with their phenotypes indicating important roles in 
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metabolism (1). Evidence to support the involvement of endo-
crine FGFs in human inherited and metabolic diseases has also 
been accumulated. We herein have reviewed the physiological/
pathophysiological roles and diagnostic/therapeutic utility of 
endocrine FGFs.
identification of endocrine FGFS
FGF15 was originally identified as a downstream target of the 
chimeric homeodomain oncoprotein E2A-Pbx1 in mice (2). 
FGF19 was also originally identified by a homology-based DNA 
database search in humans (3, 4). However, FGF19 was later 
found to be the human ortholog of mouse FGF15 (5). Only 
rodent orthologs were named FGF15. Other vertebrate orthologs 
were named FGF19.
FGF21 was originally identified by a homology-based poly-
merase chain reaction in mice and humans (6). FGF21 was later 
found to be a stimulator of glucose uptake in cultured mouse 
adipocytes (7). FGF21 was also identified as a hepatic gene induc-
ible by fasting or a ketogenic diet in mice (8, 9).
FGF23 was originally identified by a homology-based DNA 
database search in mice and humans (10). Human FGF23 was 
simultaneously identified as a gene responsible for autosomal 
dominant hypophosphatemic rickets (ADHR) characterized by 
low serum phosphate levels, rickets, osteomalacia, lower extremity 
deformities, a short stature, bone pain, and dental abscesses (11). 
Human FGF23 was subsequently found to be a causative humoral 
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FiGURe 1 | (A) Action mechanisms of FGFs. FGFs act on target cells in an 
intracrine, paracrine, or endocrine manner. (B) Schematic representations of 
FGF structures. SP, HB, and FGFR/KB indicate a secreted signal sequence, 
heparan sulfate-binding site, and FGFR/Klotho complex-binding site, 
respectively.
protein for human tumor-induced osteomalacia characterized by 
hypophosphatemia caused by renal phosphate wasting (12).
Unique Actions of endocrine FGFS with 
FGF Receptors and Klotho Coreceptors
Paracrine and endocrine FGFs, which are extracellular signal-
ing molecules, bind to and activate cell-surface FGF receptors 
(FGFRs). The human FGFR gene family comprises four members, 
FGFR1–FGFR4, that encode single-pass transmembrane proteins 
of ~800 amino acids with three extracellular immunoglobulin-
like domains I, II, and III and a split intracellular tyrosine kinase 
domain. FGFR1, FGFR2, and FGFR3 genes encode two alterna-
tive splicing variants (b and c) of immunoglobulin-like domain 
III, which is a determinant of ligand-binding specificities (1). 
Thus, there are seven FGFR proteins, FGFRs 1b, 1c, 2b, 2c, 3b, 
3c, and 4, with distinct ligand-binding specificity. The functional 
dimerization and transphosphorylation of FGFRs induced by 
FGF binding result in the activation of FGFRs, followed by the 
activation of intracellular FGF signaling pathways including 
RAS–RAF–MAPK, PI3K–AKT, STAT, and PLCγ pathways (1).
Paracrine FGFs bind to heparan sulfate proteoglycans, which 
extracellularly localize at neighboring cells as cofactors for 
FGFRs. Binding to heparan sulfate proteoglycans is essential 
for FGF signaling in a paracrine manner (Figure  1B) (1). In 
contrast, endocrine FGFs with reduced heparan sulfate-binding 
affinity are unable to function in a paracrine manner. Endocrine 
FGFs require α-Klotho or β-Klotho as a cofactor for FGFRs to 
function in an endocrine manner (1). α-Klotho and β-Klotho, 
which share structural similarities and characteristics with each 
other, are single-pass transmembrane proteins of ~1,000 amino 
acids with a short cytoplasmic domain (13). However, endocrine 
FGFs cannot efficiently bind to FGFR, α-Klotho, or β-Klotho 
alone; they efficiently bind to the FGFR–Klotho complex. The 
binding site for the FGFR–Klotho complex is localized in the 
C-terminal tail of endocrine FGF (Figure 1B) (14). FGF19 acti-
vates FGFR4 with β-Klotho and FGF21 activates FGFR1c with 
β-Klotho, whereas FGF23 activates FGFR1c with α-Klotho (1). 
FGF19 and FGF23 exhibit metabolic and proliferative activities. 
However, FGF21 is a unique FGF with metabolic activity, but no 
proliferative activity (15).
The evolutionary History of vertebrate-
Specific endocrine FGF Genes
The FGF signaling system has been conserved throughout 
metazoan evolution. The evolutionary history of the FGF gene 
family has already been proposed (5). The founder of the FGF 
family is an intracrine FGF. Intracrine FGFs, which are not 
secreted proteins, possess heparan sulfate-binding sites, but no 
secreted signal sequences. The prototype of the paracrine FGF 
subfamily was generated from the founder by gene duplication 
events early in metazoan evolution. During this evolution, 
paracrine FGFs acquired secreted signal sequences, thereby 
allowing them to function as extracellular FGFs in a paracrine 
manner. Intracrine and paracrine FGFs have been identified in 
invertebrates and vertebrates. In contrast, endocrine FGFs have 
TABLe 1 | Roles of endocrine FGFs indicated by their knockout 
mouse phenotypes.
FGF15 Morphogenesis of the cardiac outflow tract (2, 19), hepatic bile 
acid metabolism (20), gallbladder filling (21), hepatic protein 
and glycogen metabolism (22), liver regeneration (23, 24), and 
fibrosis-induced hepatocellular carcinogenesis (25)
FGF21 Lipolysis in white adipose tissue (28), adaptation to a ketogenic 
diet (29, 30), upstream effector of adiponectin (31, 32), glucagon 
action (33), pancreatic beta-cell proliferation and insulin synthesis 
(34), adaptation to ER stress (35), cardiac hypertrophy  
(36, 37), pancreatitis (38), diabetic cardiomyopathy (39), and aortic 
remodeling (40)
FGF23 Renal phosphate and active vitamin D metabolism (41) and ear 
development and function (42)
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Vertebrates
Intracellular  signal Extracellular  signal 
Neuronal function Development Metabolism
Heparan sulfate-binding site
FGFR/Klotho-binding site 
Evolution
Structural Motif
Function
FiGURe 2 | The functional evolutionary history of the FGF family.
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been detected in vertebrates, but not invertebrates, indicating 
that they are specific to vertebrates (Figure  2). The prototypic 
endocrine FGF was generated from the prototype of paracrine 
FGF by local gene duplication early in vertebrate evolution. 
FGF19, FGF21, and FGF23 were subsequently generated from 
the prototype by two large-scale genome duplication events early 
in vertebrate evolution (5). Endocrine FGFs lost heparan sulfate-
binding affinity and acquired FGFR/Klotho complex-binding 
affinity for a systemic signaling system in an endocrine manner 
during their evolution (5). FGF19 and FGF23 have been identi-
fied in all vertebrates examined, including teleosts, amphibians, 
reptiles, birds, and mammals. However, FGF21 was not detected 
in any birds examined, indicating that FGF21 was lost in the avian 
lineage (16, 17). The avian genome is principally characterized 
by its constrained size with the loss of many genes in the avian 
lineage, indicating that pan-avian genomic diversity covaries with 
adaptations to different lifestyles and the convergent evolution of 
traits (18).
Roles of endocrine FGFs indicated by 
Their Knockout Mouse Phenotypes
The mouse is a mammalian model that is useful for investigating 
gene functions. All endocrine FGF knockout mice have been 
extensively analyzed, indicating their important physiological 
roles in metabolism (Table 1).
FGF15
FGF15 knockout mice survive until E10.5, but then gradually die 
due to defects in the cardiac outflow tract, indicating that FGF15 
is required for proper morphogenesis of the cardiac outflow 
tract during embryonic development in the heart (2, 19). FGF15 
is selectively expressed in the ileum at postnatal stages, and a 
small number of FGF15 knockout mice survive until postnatal 
stages, which suggests that FGF15 plays crucial roles in regulating 
hepatic bile acid synthesis and gallbladder filling in an endocrine 
manner (20, 21). Surviving FGF15 knockout mice also fail to 
properly maintain blood concentrations of glucose and normal 
postprandial amounts of liver glycogen, indicating that FGF15 is 
a postprandial, insulin-independent activator of hepatic protein 
and glycogen synthesis (22). Surviving hepatectomized FGF15 
knockout mice exhibit severe defects in liver regeneration, indi-
cating that FGF15 also plays a role in liver regeneration (23, 24). 
Ileal FGF15 expression is increased in mice undergoing carcino-
genesis. Fibrosis-induced hepatocellular carcinogenesis results 
in fewer and smaller tumors in surviving FGF15 knockout mice 
than in wild-type mice, suggesting that ileal FGF15 enhances the 
development of carcinoma (25).
FGF21
FGF21 is expressed in the liver, pancreas, white adipose tis-
sue, and muscle of mice (6, 26, 27). The phenotypes of FGF21 
knockout mice, which are viable and fertile, indicate that FGF21 
stimulates lipolysis in the white adipose tissue during feeding, 
but inhibits it during fasting (28). FGF21 knockout mice fed a 
ketogenic diet also indicate that FGF21 plays a role in the adapta-
tion to a ketogenic diet and impairs adipocyte insulin sensitivity 
(29, 30). FGF21 knockout mice also indicate that FGF21 is an 
upstream effector of adiponectin in white adipocytes and that 
adiponectin also mediates many of the systemic effects of FGF21 
on energy metabolism and insulin sensitivity in the liver and 
skeletal muscle (31, 32). Glucagon, an essential regulator of 
glucose homeostasis, modulates lipid metabolism and promotes 
weight loss. Glucagon receptor activation increases hepatic 
FGF21 expression in mice. FGF21 knockout mice indicate that 
FGF21 contributes, at least in part, to glucose, energy, and lipid 
metabolism controlled by glucagon (33). FGF21 knockout mice 
also exhibit insulin resistance, while being normoglycemic, and 
this is associated with increases in pancreatic beta-cell prolifera-
tion and insulin synthesis, which act as compensatory responses. 
This resistance results from enhanced growth hormone sensitiv-
ity in FGF21 knockout pancreatic islets, indicating that FGF21 is 
important in the regulation of pancreatic beta-cell proliferation 
and insulin synthesis, possibly via the modulation of growth hor-
mone signaling (34). Endoplasmic reticulum (ER) stress leads 
to the development and progression of various diseases such as 
obesity and diabetes. ER stress induces hepatic FGF21 expres-
sion. ER stress and hepatic lipid accumulation are increased in 
FGF21 knockout mice, indicating that FGF21 plays a role in the 
adaptive responses to ER stress (35). FGF21 knockout mice also 
have an increased relative heart weight and develop enhanced 
TABLe 2 | Roles of endocrine FGFs indicated by human diseases.
inherited disease with loss-of-function mutations
FGF23 Hyperphosphatemic familial tumoral calcinosis (45, 46)
inherited disease with gain-of-function mutations
FGF23 Autosomal dominant hypophosphatemic rickets (11, 47)
Paraneoplastic diseases with gain-of-function
FGF19 Extrahepatic cholestasis (43)
FGF23 Osteomalacia (12)
SNPS as potential risk factors for diseases
FGF21 Intake of dietary macronutrients (48), metabolic syndrome, 
obesity, and diabetes (49)
FGF23 Cardiac abnormalities in Kawasaki disease (50) and prostate 
cancer (51)
Serum levels as biomarkers for diseases
FGF19 Renal failure (52, 53), coronary artery disease (54), intestinal 
failure-associated liver disease (55), diabetes (56), Crohn’s 
disease (57, 58), and prostate cancer (60)
FGF21 Renal failure (61), cardiovascular disease (62–64), mitochondrial 
disease (65, 66), obesity and diabetes (56, 67–70), anorexia 
nervosa (71), Cushing’s syndrome (72), Brown adipose tissue 
activity (73), non-alcoholic fatty liver disease (74, 75), chronic 
hepatitis C with steatosis (76), systemic inflammatory response 
syndrome (77), and rheumatoid arthritis (78)
FGF23 Renal failure (79–81), cardiovascular failure (82–86), and stroke 
(87, 88)
September 2015 | Volume 6 | Article 1544
Itoh et al. Endocrine FGFs as metabolic regulators
Frontiers in Endocrinology | www.frontiersin.org
signs of dilatation. FGF21 is markedly secreted by cardiac cells 
in response to cardiac stress. Thus, the heart appears to be a 
target of locally generated FGF21, indicating that FGF21 acts 
on cardiomyocytes, possibly in a paracrine manner (36). FGF21 
prevents the production of reactive oxygen species in cardiac cells 
by acting as an antioxidant factor in the heart, thereby prevent-
ing pro-oxidative pathways under inflammatory or hypertrophic 
conditions (37). The expression of FGF21 in pancreatic acinar 
cells is markedly increased during cerulein-induced pancreatitis. 
FGF21 knockout mice have higher serum amylase levels and 
more tissue damage, suggesting a novel function for FGF21 as an 
immediate response gene protecting pancreatic acini from overt 
damage (38). FGF21 knockout mice with streptozotocin-induced 
diabetes exhibit severe cardiac dysfunction, increased cardiac 
lipid accumulation, and severe aortic remodeling, indicating 
that FGF21 plays roles in the development and progression of 
diabetic cardiomyopathy and aortic remodeling (39, 40).
FGF23
FGF23 is mainly expressed in osteocytes in mice. FGF23 
knockout mice survive until birth, but then gradually die by 
11 weeks after birth. The phenotypes of FGF23 knockout mice 
indicate that osteocytic FGF23 is a regulator for phosphate and 
active vitamin D metabolism in the kidney (41). FGF23 is also 
ubiquitously expressed throughout the cochlea. FGF23 het-
erozygous knockout mice are profoundly deaf with moderate 
hearing loss and a near-normal morphology. However, FGF23 
homozygous knockout mice have dysplastic bulla and ossicles. 
These findings indicate that FGF23 is critical for normal devel-
opment of the middle ear as well as the functions of the middle 
and inner ear (42).
Roles of endocrine FGFs indicated by 
Human Diseases
Evidence has been accumulated to support the involvement of 
FGF19 and FGF23 in human diseases and also indicates their 
crucial pathophysiological roles in diseases (Table 2).
FGF19
Paraneoplastic Diseases with Gain-of-Function
Extrahepatic cholestasis is a condition in which the release of 
bile acid is blocked in the bile ducts. Cholestasis is caused by 
a pancreatic tumor. Markedly increased serum FGF19 levels 
and the abundant expression of hepatic FGF19 are observed in 
cholestatic patients, indicating that FGF19 signaling is involved 
in some of the adaptations that protect the liver against bile acid 
toxicity (43).
FGF23
Inherited Disease with Loss-of-Function Mutations
Hyperphosphatemic familial tumoral calcinosis (HFTC) is a 
rare autosomal recessive metabolic disorder characterized by 
the deposition of calcium phosphate crystals. HFTC was initially 
attributed to loss-of function mutations in GLANT3 encoding a 
glycosyltransferase (44). Loss-of-function mutations in FGF23 
are also associated with HFTC (45, 46).
Inherited Disease with Gain-of-Function Mutations
Autosomal dominant hypophosphatemic rickets is character-
ized by isolated renal phosphate wasting, hypophosphatemia, 
and inappropriately normal 1,25-dihydroxyvitamin D3 levels. 
Gain-of-function mutations in FGF23 result in AHDR. Cleaved 
FGF23 forms due to intracellular proteolysis lose their biological 
activities. FGF23 mutations in ADHR result in impaired pro-
teolysis of FGF23, resulting in increased serum levels of active 
FGF23 (11, 47).
Paraneoplastic Diseases with Gain-of-Function
Osteomalacia is characterized by the softening of bones due to 
defective bone mineralization. Tumors that overexpress FGF23 
induce tumor-induced osteomalacia characterized by hypophos-
phatemia, which is caused by renal phosphate wasting (12).
Single-Nucleotide Polymorphisms in 
endocrine FGF Genes as Potential Risk 
Factors for Diseases
Single-nucleotide polymorphisms (SNPs) are DNA sequence 
variations that commonly occur within a population (e.g., 1%) 
with a single nucleotide in the genome. These SNP variations 
underlie differences in the susceptibility of humans to diseases. 
The severity of illnesses and the responses of the human body to 
treatments are also manifestations of SNPs. SNPs in endocrine 
FGFs also suggest their potential roles in risk factors for diseases 
(Table 2).
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FGF21
The intake of dietary macronutrients such as carbohydrates, 
protein, and fat is associated with the risk of obesity and diabetes. 
A SNP located in the exon of FGF21 is significantly associated 
with the percentage of total caloric intake from protein and 
carbohydrates, indicating that FGF21 is a potential susceptibility 
gene for obesity and diabetes (48). SNPs in the 3′ untranslated 
region of FGF21 are also associated with metabolic syndrome, 
obesity, and diabetes (49). However, the mechanisms underlying 
these associations currently remain unclear.
FGF23
Kawasaki disease, which is a systemic panvasculitis that affects all 
medium/small-sized vessels, mainly occurs in early childhood and 
increases the risk of cardiac abnormalities. A SNP in the intron of 
FGF23 is significantly associated with higher serum FGF23 levels 
and cardiac abnormalities in children with Kawasaki disease 
(50). Three distinct SNPs in FGF23 are also associated with an 
increased risk of prostate cancer, indicating that FGF23 genetic 
variations increase prostate cancer susceptibility (51).
Serum endocrine FGF Levels as 
Biomarkers for Diseases
Endocrine FGFs mainly play roles in an endocrine manner via 
the blood circulation system. Serum endocrine FGFs levels are 
sometimes altered in patients with metabolic and other diseases, 
indicating that endocrine FGFs are biomarkers for these diseases 
(Table 2).
FGF19
Renal Failure
Renal failure is a condition in which the kidneys fail to adequately 
filter waste products from the blood. Serum FGF19 levels are 
significantly increased in end-stage renal failure patients with 
chronic hemodialysis (52). The postprandial FGF19 response in 
serum is blunted in chronic kidney disease and is also associated 
with impaired insulin and C-peptide signaling (53).
Cardiovascular Disease
Coronary artery disease (CAD) is a group of diseases including 
stable angina, unstable angina, myocardial infarction, and sud-
den coronary death. Serum FGF19 levels are decreased in CAD 
in relation to its severity, suggesting that reductions in the expres-
sion of FGF19 are involved in the development and progression 
of CAD (54).
Intestinal Failure-Associated Liver Disease
In pediatric intestinal failure (IF), serum FGF19 levels are 
decreased corresponding to IF-associated liver disease (IFALD). 
This suggests that FGF19 contributes to the pathogenesis of 
IFALD (55).
Energy Metabolism Disorder
Serum FGF19 levels are decreased in patients with type 2 diabe-
tes, indicating that the FGF19 pathway is significantly perturbed 
in severe diabetes (56).
Bile Acid Metabolism Disorder
Bile acids are reabsorbed by the terminal ileum. However, their 
reabsorption is frequently impaired in Crohn’s disease, resulting in 
secretory diarrhea. Serum FGF19 levels are decreased in Crohn’s 
disease associated with diarrhea and disease activity, indicating 
that FGF19 has potential as a biomarker for the functioning ileum 
in Crohn’s disease (57, 58). However, serum FGF19 levels are not 
affected in gallstone carriers (59).
Cancer
Serum FGF19 levels in the high Gleason grade of prostate cancer 
are higher than those in the low Gleason grade group, indicating 
that FGF19 promotes the progression of prostate cancer (60).
FGF21
Renal Failure
Serum FGF21 levels are increased in chronic kidney disease and 
acute kidney dysfunction, suggesting that renal excretion is a 
major route for the elimination of FGF21 (61).
Cardiovascular Disease
Coronary heart disease (CHD) is characterized by the narrowing 
of small blood vessels in the heart, which may lead to heart attacks. 
Serum FGF21 levels are significantly increased in CHD. Serum 
FGF21 levels in CHD patients with diabetes, hypertension, or 
both are higher than those in patients without these comorbidities. 
High serum FGF21 levels are associated with adverse lipid pro-
files in CHD patients, indicating that the paradoxical increase in 
serum FGF21 levels in CHD patients is a compensatory response 
or resistance to FGF21 (62). Serum FGF21 levels are positively 
correlated with carotid intima-media thickness (IMT) in women, 
but not in men, indicating that elevated serum FGF21 levels in 
women are an independent risk factor for increased carotid 
IMT (63). Preeclampsia, a serious cardiovascular complication 
in pregnancy, is associated with an increased future metabolic 
and cardiovascular risk. Serum FGF21 levels are significantly 
increased in patients with preeclampsia during pregnancy (64).
Mitochondrial Disease
Mitochondrial disease caused by dysfunctional mitochondria 
is a group of disorders with highly variable phenotypes includ-
ing mitochondrial myopathy, diabetes mellitus, deafness, optic 
neuropathy, and multiple sclerosis-type disease. Serum FGF21 
levels are significantly increased in human mitochondrial 
disease and the best predictor of mitochondrial disease among 
classical indicators including creatine kinase, lactate, and 
 pyruvate (65, 66).
Energy Metabolism Disorder
Serum FGF21 levels are significantly increased in patients with 
obese and type 2 diabetes, suggesting the direct positive meta-
bolic effects of FGF21 (56, 67–70). Anorexia nervosa (AN) is an 
eating disorder that is characterized by a low weight and food 
restriction. Serum FGF21 levels are significantly decreased in 
AN, suggesting that FGF21 is involved in the pathophysiology 
of or a complex adaptive response to AN (71). Cushing’s syn-
drome is caused by prolonged exposure to inappropriately high 
levels of glucocorticoids. Serum FGF21 levels are increased in 
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patients with Cushing’s syndrome. Increased serum FGF21 levels 
are attributed to their excessive fat accumulation and related 
metabolic abnormalities, but not to the direct effects of cortisol 
on the production of FGF21 (72). Brown adipose tissue, which 
contains a markedly higher number of mitochondria, generates 
body heat in animals without shivering. Since brown adipose 
tissue is expected to markedly contribute to energy homeostasis 
in humans, it may represent a therapeutic target of obesity. Serum 
FGF21 levels are associated with brown adipose tissue activity, 
indicating a novel mechanism by which brown adipose tissue 
activity may be enhanced (73).
Lipid Metabolism Disorder
Serum FGF21 levels are increased in patients with non-alcoholic 
fatty liver disease (NAFLD), which supports the role of FGF21 as 
a key regulator of hepatic lipid metabolism (74). In contrast to 
adults with NAFLD, serum FGF19 and FGF21 levels are inversely 
associated with hepatic damage in children with NAFLD, pro-
viding insights for a better understanding of the progression of 
NAFLD (75).
Infection and Inflammation
Hepatitis C (HC) is an infectious disease that is caused by the HC 
virus. Serum FGF21 levels are increased in chronic HC (CHC) 
patients with steatosis and are associated with the steatosis grade, 
which may be a useful diagnostic marker for determining hepatic 
steatosis in CHC (76). Sepsis is an illness in which the body has 
a severe response to infection. Systemic inflammatory response 
syndrome (SIRS) is an inflammatory state in the whole body due 
to the response of the immune system to infection. SIRS is also 
closely related to sepsis. Serum FGF21 levels are significantly 
increased in patients with sepsis and SIRS, suggesting a role 
for FGF21 in inflammation (77). Rheumatoid arthritis (RA) is 
a chronic inflammatory disease in small hand and foot joints. 
Serum FGF21 levels are significantly increased in patients with 
RA, indicating the compensatory response of FGF21 to inflam-
mation and immune response (78).
FGF23
Renal Failure
Serum FGF23 levels are significantly increased in chronic kidney 
disease, indicating the important role of FGF23 in maintaining 
a neutral phosphate balance as the glomerular filtration rate 
decreases (79–81).
Cardiovascular Disease
Serum FGF23 levels are positively correlated with the risk of 
heart failure (82). Serum FGF23 levels are increased in children 
with heart failure (83). These findings indicate that increased 
serum FGF23 levels are a risk factor for heart failure. Serum 
FGF23 levels are also increased in association with angio-
graphic severity and the extent of CAD (84). Increased serum 
FGF23 levels are also a risk factor for myocardial infraction 
and hemorrhagic stroke (85). Serum FGF23 levels are strongly 
associated with left ventricular hypertrophy (86). These find-
ings provide additional evidence for the role of FGF23 in 
cardiovascular disease.
Stroke
Stroke is a disease that is caused by cutting off the blood supply 
to part of the brain (ischemic) or by bleeding into the surround-
ing brain tissue from a weakened vessel (hemorrhagic). Serum 
FGF23 levels are increased in patients with stroke (87, 88).
Therapeutic Utility of endocrine FGFs in 
Humans or Monkeys
FGF19
FGF19 is expected to prevent bile acid-induced liver damage by 
reducing hepatic bile acid levels through the modulation of bile 
acid synthesis. However, since FGF19 also stimulates the prolifera-
tion of hepatocytes, the potential risk associated with prolonged 
exposure to supraphysiological levels of FGF19 represents a major 
hurdle in the development of an FGF19-based therapy in hepa-
tocellular carcinogenesis. A manufactured FGF19 variant, M70, 
which carries three amino acid substitutions and a five-amino acid 
deletion, regulates bile acid metabolism without tumorigenicity 
(89). The administration of M70 to healthy human volunteers 
potently reduces serum levels of 7α-hydroxy-4-cholesten-3-
one, a surrogate marker for the hepatic activity of cholesterol 
7α-hydroxylase (CYP7A1), which catalyzes the rate-limiting step 
in the bile acid synthetic pathway. These findings indicate that the 
development of non-tumorigenic FGF19 variants represents an 
effective approach for the prevention and treatment of cholestatic 
liver diseases and other disorders associated with bile acid dys-
regulation (89) (Table 3).
FGF21
The daily administration of FGF21 to diabetic rhesus monkeys for 
6 weeks induces marked reductions in fasting serum glucose, tri-
glyceride, insulin, and glucagon levels, significant improvements in 
lipoprotein profiles, and significant weight loss, thereby supporting 
the development of FGF21 for the treatment of diabetes and other 
metabolic diseases in humans (90). LY2405319 (LY) is a manufac-
tured FGF21 variant with significantly improved biopharmaceutical 
properties (91). The administration of LY to patients with obesity 
and type 2 diabetes for 28 days produces significant improvements 
in dyslipidemia, a shift to a potentially less atherogenic apolipopro-
tein concentration profile, and favorable effects on body weight. 
These findings indicate that FGF21-based therapies may be effective 
for the treatment of selected metabolic disorders (92).
FGF21 has a short half-life (1–2 h). Fc-FGF21 is a long-acting 
FGF21 variant that is generated by fusing with an Fc fragment. In 
obese rhesus monkeys treated with FGF21 (once a day) or Fc-FGF21 
TABLe 3 | Therapeutic utility of endocrine FGFs in humans or monkeys.
FGF19 Cholestatic liver disease and bile acid  
dysregulation (89)
FGF21 Diabetes and metabolic disease (90)
FGF21 variant (LY2405319) Obesity and metabolic disease (91, 92)
FGF21 variant (Fc-FGF21) Diabetes (93)
FGF21 variant (PF-05231023) Diabetes (94)
FGF21 Avimer Obesity (95)
Anti-FGF23 (KRN23) X-linked hypophosphatemia (96, 97)
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(once a week), serum glucose, insulin, cholesterol, and triglyceride 
levels and body weight are markedly lower with Fc-FGF21 than 
with FGF21, indicating that the administration of Fc-FGF21 once 
a week leads to similar or greater efficacy than FGF21 adminis-
tered daily (93). PF-05231023 is also a long-acting FGF21 variant 
generated by covalently conjugating FGF21 molecules to a non-
targeting human IgG1 κ scaffold. Single intravenous injection of 
PF-05231023 to type 2 diabetes mellitus patients decreases serum 
triglyceride, total cholesterol, and low-density lipoprotein cho-
lesterol levels and increases high-density lipoprotein cholesterol 
levels, but have no apparent effect on glucose levels (94).
As an alternative to FGF21, bispecific Avimer polypeptides 
that bind with high affinity and specificity to one of the receptor 
and coreceptor pairs used by FGF21, FGFR1c, and β-Klotho have 
been generated. These Avimers exhibit FGF21-like activity with 
greater potency than FGF21 in vitro. In obese male cynomolgus 
monkeys, a bispecific Avimer exhibits improved metabolic 
parameters and leads to greater reductions in body weight 
than those with FGF21, thereby supporting a novel therapeutic 
approach to target this potentially important pathway in the treat-
ment of diabetes and obesity (95).
FGF23
X-linked hypophosphatemia (XLH) with elevated serum FGF23 
levels is the most common heritable form of rickets and osteo-
malacia. KRN23 is a human anti-FGF23 antibody that has been 
developed as a potential treatment for XLH patients. KRN23 
significantly increases the maximum renal tubular threshold for 
phosphate reabsorption, serum phosphate, and 1,25-dihydroxy-
vitamin D in XLH patients, suggesting utility for KRN23 in XLH 
patients (96, 97).
Conclusion
Endocrine FGFs comprising FGF19, FGF21, and FGF23 require 
FGFR and α-Klotho or β-Klotho as a cofactor for FGFR for their 
signaling in an endocrine manner. Endocrine FGFs lost heparan 
sulfate-binding affinity and acquired systemic signaling system 
with α-Klotho or β-Klotho during their evolution. The pheno-
types of endocrine FGF knockout mice indicate that endocrine 
FGFs play important physiological roles in metabolism including 
bile acid metabolism, energy metabolism, and phosphate/active 
vitamin D metabolism. Evidence for the involvement of endo-
crine FGFs in human inherited and metabolic diseases has also 
been increasing, indicating their crucial pathophysiological roles 
in metabolic diseases, their SNPs as potential risk factors for dis-
eases, and their serum levels as useful biomarkers for metabolic 
diseases. Furthermore, the therapeutic utility of endocrine FGFs 
is currently being developed. These findings provide new insights 
into the physiological and pathophysiological roles of endocrine 
FGFs and may provide potential diagnostic and therapeutic 
strategies for metabolic diseases.
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